Skip to content

Scailyte Extends Series A to USD 8 Million

Scailyte Extends Series A to USD 8 Million

Scailyte Extends Series A to USD 8 Million

Scailyte Extends Series A to USD 8 Million

We are thrilled to announce the extension of our Series A funding, bringing the total raised amount to USD 8 million.

 

Accelerating Innovation and Expanding Horizons

These additional resources will play a pivotal role in accelerating Scailyte’s impact in the immuno-oncology landscape, expanding our business partnerships and market footprint. We are committed to solidifying our position as a leading biomarker discovery and translational platform harnessing the power of single-cell omics and proprietary AI algorithms.

Peter Nestorov, CEO & co-founder, shares his excitement, “In the past year, we have gained significant commercial traction, validating the market need for an unbiased and powerful biomarker discovery approach, which delivers reliable and translatable insights from small patient populations. With the newly raised funds, we will expand our presence in the US market, seeking further partnerships with like-minded biotech and pharma companies in the precision oncology space.” 

Pascal Koenig, Chair of the Board of Directors, comments,This additional investment is a testament to the long-term trust and recognition of Scailyte’s potential and tireless efforts. It reaffirms our commitment to advancing the field of precision oncology.” 

Thank you for your unwavering support on our journey to transform oncology research. Together, we’re making a difference!

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News

World CB & CDx Summit 2024

Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...

Read more

Recent News

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Recent News

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Recent News

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

01 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

02 /04

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

World CB & CDx Summit 2024

Scailyte is thrilled to attend Hanson Wade's 14th World CB & CDx Summit - the flagship CDx event of ...

Read more

Recent News

03 /04

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

04 /04

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News